The side effects of OCA, such as cutaneous pruritus and nausea, are significant factors limiting its clinical application.34 Therefore, developing local drug delivery systems composed of biomaterials could serve as a more effective carrier for testing the effects of osteoblast-specific FXR in the treatment of osteoporosis. The gene discussed is NR1H4; the disease is osteoporosis.